Knights of Columbus Asset Advisors’s AstraZeneca AZN Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,141	Closed	-$210K	–	399
2025 Q4	$210K	Hold	1,141	–	–	0.01%	343
2025 Q3	$175K	Buy	1,141 +27	+2%	+$4.09K	0.01%	327
2025 Q2	$156K	Hold	1,114	–	–	0.01%	323
2025 Q1	$164K	Sell	1,114 -54	-5%	-$7.81K	0.01%	306
2024 Q4	$153K	Buy	1,168 +643	+122%	+$90K	0.01%	315
2024 Q3	$81.8K	Buy	525 +49	+10%	+$7.91K	0.01%	341
2024 Q2	$74.2K	Hold	476	–	–	﹤0.01%	364
2024 Q1	$64.5K	Sell	476 -32	-6%	-$4.24K	﹤0.01%	352
2023 Q4	$68.4K	Hold	508	–	–	﹤0.01%	358
2023 Q3	$68.8K	Buy	508 +28	+6%	+$3.82K	0.01%	356
2023 Q2	$68.7K	Buy	+480	New	+$70.6K	0.01%	357

Other funds holding AZN

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Asset Management London, Ec4n 8af $148B AUM

Knights of Columbus Asset Advisors's AZN Position: Q1 2026 in Review

Knights of Columbus Asset Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 1,141 shares — an estimated $210K sold.

Knights of Columbus Asset Advisors first reported a position in AZN in Q2 2023 and held it in 11 quarters. The position peaked at $210K in Q4 2025. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Knights of Columbus Asset Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 1,141 AstraZeneca shares in Q1 2026, an estimated $210K.
Knights of Columbus Asset Advisors first reported a position in AstraZeneca in Q2 2023 and held it in 11 quarters.
Knights of Columbus Asset Advisors's AstraZeneca position peaked at $210K in Q4 2025.
1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Knights of Columbus Asset Advisors's 13F filing for Q1 2026, filed 11 May 2026.